Free prostate-specific antigen in serum is becoming more complex

Urology

Volumn 59, Issue 6, 2002, Pages 797-802

  Mikolajczyk, Stephen D ^a   Marks, Leonard S ^b   Partin, Alan W ^c   Rittenhouse, Harry G ^a  

^a Hybritech Incorporated   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR;

CANCER GRADING; CANCER RISK; CANCER TISSUE; CORRELATION FUNCTION; EPITHELIUM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE FLUID; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SEMINAL PLASMA; SERUM; WESTERN BLOTTING;

ALPHA 1-ANTICHYMOTRYPSIN; ANTIBODIES, MONOCLONAL; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; SEMEN; SENSITIVITY AND SPECIFICITY;

EID: 0036093686     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01605-3     Document Type: Review

References (43)

1. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
2. Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
3. Serum prostate specific antigen as pre-screening test for prostate cancer
4. 1-antichymotrypsin
5. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
6. Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen
7. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
8. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
9. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum
10. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue
11. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
12. Identification of precursor forms of prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry
13. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer
14. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2
15. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes
16. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate
17. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR
18. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer
19. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors
20. Immunohistochemical staining of prostate cancer with a monoclonal antibody to the precursor of prostate-specific antigen
21. Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels
22. Characterization of the precursor of prostate-specific antigen - Activation by trypsin and by human glandular kallikrein
23. Seminal plasma contains "BPSA," a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia
24. BPSA is a potential serum marker for benign prostatic hyperplasia (BPH)
25. Prostate specific antigen in benign prostatic hyperplasia: Purification and characterization
26. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo
27. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia
28. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid
29. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells
30. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA
31. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146
32. Measurement of complexed PSA improves specificity for early detection of prostate cancer
33. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
34. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
35. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
36. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis
37. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium
38. l-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia
39. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications
40. Analysis of free prostate-specific antigen (PSA) after chemical release from the complex with alpha(1)-antichymotrypsin (PSA-ACT)
41. Serum percent free prostate-specific antigen in metastatic prostate cancer
42. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy
43. Prostate-specific antigen density: Correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis